Is ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 77.1% / 30% | 57.1% / 30% | 4.6% / 30% | 3.86% / 5% | ✗ NOT HALAL |
| DJIM | 77.1% / 33% | 57.1% / 33% | 4.6% / 33% | 3.86% / 5% | ✗ NOT HALAL |
| MSCI | 63.7% / 33% | 47.2% / 33% | 3.8% / 33% | 3.86% / 5% | ✗ NOT HALAL |
| S&P | 77.1% / 33% | 57.1% / 33% | 4.6% / 33% | 3.86% / 5% | ✗ NOT HALAL |
| FTSE | 63.7% / 33% | 47.2% / 33% | 3.8% / 50% | 3.86% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 91.5% | |
| Operating Margin | -193.3% | |
| Net Margin | -216.5% | |
| Return on Equity (ROE) | -154.6% | |
| Return on Assets (ROA) | -23.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$111M |
| Free Cash Flow | -$136M |
| Total Debt | $1.7B |
| Debt-to-Equity | 148.4 |
| Current Ratio | 1.8 |
| Total Assets | $2.6B |
Price & Trading
| Last Close | $21.30 |
| 50-Day MA | $24.09 |
| 200-Day MA | $33.01 |
| Avg Volume | 3K |
| Beta | 0.9 |
|
52-Week Range
$17.55
| |
About ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ASCENTAGE PHARMA GROUP INTERNATIONAL is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ASCENTAGE PHARMA GROUP INTERNATIONAL's debt ratio?
ASCENTAGE PHARMA GROUP INTERNATIONAL's debt ratio is 77.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 63.7%.
What are ASCENTAGE PHARMA GROUP INTERNATIONAL's key financial metrics?
ASCENTAGE PHARMA GROUP INTERNATIONAL has a market capitalization of $2.2B, and revenue of $981M. The company maintains a gross margin of 91.5% and a net margin of -216.5%. Return on equity stands at -154.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.